Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of AR103055A1publicationCriticalpatent/AR103055A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Reivindicación 1: Un método para tratar la degeneración de la retina; el método comprende administrar al ojo de un sujeto una población de células derivadas del posparto, en donde la población de células segrega moléculas puente, y en donde las moléculas puente se seleccionan de MFG-E8, Gas6, TSP-1 y TSP-2.Claim 1: A method of treating retinal degeneration; The method comprises administering to the eye of a subject a population of cells derived from the postpartum, where the population of cells secretes bridging molecules, and where the bridging molecules are selected from MFG-E8, Gas6, TSP-1 and TSP-2.
ARP150104114A2014-12-162015-12-16
TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS
AR103055A1
(en)
Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders